Immunotherapy

Significant disparities exist between patients with peanut allergies who are currently receiving oral immunotherapy and those who are not, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Families of children with peanut allergies that pursued oral immunotherapy cited remission and the potential for disease modification as their reason, according to a study published in The Journal of Allergy and Immunology: In Practice.

Compared with non-Hispanic white individuals, patients from racial and ethnic minority groups experienced similar clinical benefits when participating in phase 1 trials for advanced cancers, data published in JAMA Network Open showed.

Gut microbiomes in children with food allergy may differ from those without food allergy, with fewer differences seen in younger children, according to a study published in Annals of Allergy, Asthma and Immunology.

Participants with an allergy to cow’s milk had the lowest rate of oral immunotherapy treatment discontinuation, according to a study published in Annals of Allergy, Asthma and Immunology.

As asthma and allergy continue to affect more people, the importance of advanced practitioners in enhancing patient safety, addressing health care disparities and increasing treatment access has come to the forefront of patient care.

FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.

In this video, Ronny Drapkin, MD, discusses how PARP inhibitors changed the field of ovarian cancer treatment.

Prior radiotherapy was associated with progression-free survival in patients with metastatic cutaneous squamous cell carcinoma treated with cemiplimab, according to a study.

Jae Park, MD, compared the moment to a baby being born.